Eleven Biotherapeutics: Oppenheimer & Co. Healthcare Conference (Epizyme) - Dec 13, 2014 - “Well Tolerated and Biologically Active In EE50 Patient Population“; “Results from phase 1b/2a: EBI-005 (5 & 20 mg/mL) was well tolerated with no SAEs reported, No drug detected in serum levels and no evidence of drug-specific antibodies, Significant reduction in the use of artificial tears for EBI-005 treated subjects in EE population“
P1/2 data • Immunology
|